RWE: France
Efficacy
PFS in matched population
ORR
61%
CR
39%
OS at 12 months
45%
| Safety | |
|---|---|
| CRSGrade ≥3 | 8% |
| ICANSGrade ≥3 | 3% |
Limitations: Efficacy outcomes only reported for matched populations
- Reference: 1. Bachy E et al. Nat Med. 2022;28(10):2145–2154.
Data collection
Dec 2019–Oct 2021
DESCAR-T French CAR-T registry
Median follow-up
months
No. of patients infused with tisa-cel
(209 in matched data set)
| Median age (range) years | 64 (20–81) |
| Gender (male) | 60% |
| ECOG ≥2 | 13% |
| IPI | aaIPI 2: 50%aaIPI 3: 8% |
| HG lymphoma(double or triple hit) | NR |
| DLBCL NOS or HGBCL | 79% |
| Transformed lymphoma | 16% |
| Comorbidities | NR |
| LDH elevated | 56% ≥N |
| Prior therapies (median)≥3 lines | 354% |
| Primary refractoryRefractory to last lineRelapsed | NRNRNR |
| Prior SCTAutoAllo | 22%NR |
| Bridging therapy | 86% |
Limitations: Results only available in matched population while baseline characteristics provided for all infused; significant number of patients excluded from matching
- Reference: 1. Bachy E et al. Nat Med. 2022;28(10):2145–2154.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete